Stephen Schlachter
Overview
Explore the profile of Stephen Schlachter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Russell A, DuVall M, Barthel B, Qian Y, Peter A, Newell-Stamper B, et al.
J Clin Invest
. 2023 Mar;
133(10).
PMID: 36995778
Duchenne muscular dystrophy (DMD) is a lethal muscle disease caused by absence of the protein dystrophin, which acts as a structural link between the basal lamina and contractile machinery to...
2.
Blake J, Xu R, Bencsik J, Xiao D, Kallan N, Schlachter S, et al.
J Med Chem
. 2012 Sep;
55(18):8110-27.
PMID: 22934575
The discovery and optimization of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compounds that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported. The initial design and optimization was guided by the...
3.
Ren L, Wenglowsky S, Miknis G, Rast B, Buckmelter A, Ely R, et al.
Bioorg Med Chem Lett
. 2011 Jan;
21(4):1243-7.
PMID: 21251822
The development of inhibitors of B-Raf(V600E) serine-threonine kinase is described. Various head-groups were examined to optimize inhibitor activity and ADME properties. Several of the head-groups explored, including naphthol, phenol and...
4.
Buckmelter A, Ren L, Laird E, Rast B, Miknis G, Wenglowsky S, et al.
Bioorg Med Chem Lett
. 2011 Jan;
21(4):1248-52.
PMID: 21211972
Virtual and high-throughput screening identified imidazo[1,2-a]pyrazines as inhibitors of B-Raf. We describe the rationale, SAR, and evolution of the initial hits to a series of furo[2,3-c]pyridine indanone oximes as highly...